

## COMPENDIA TRANSPARENCY TRACKING FORM FOR ONCOLOGY OFF-LABEL USES DERIVED FROM GUIDELINES

**DATE:** March 1, 2025

**DRUG NAME:** Tislelizumab-jsgr

**OFF-LABEL USE:** Liver carcinoma, unresectable

COMPENDIA TRANSPARENCY REQUIREMENTS	
1	Provide criteria used to evaluate/prioritize the request (therapy)
2	Disclose evidentiary materials reviewed or considered
3	Provide names of individuals who have substantively participated in the review or disposition of the request and disclose their potential direct or indirect conflicts of interest
4	Provide meeting minutes and records of votes for disposition of the request (therapy)

**EVALUATION/PRIORITIZATION CRITERIA:** C, \*to meet requirement 1(C, L, R, S)

CODE	EVALUATION/PRIORITIZATION CRITERIA
A	Treatment represents an established standard of care or significant <b>advance</b> over current therapies
C	<b>Cancer</b> or cancer-related condition
E	Quantity and robustness of <b>evidence</b> for use support consideration
L	<b>Limited</b> alternative therapies exist for condition of interest
P	<b>Pediatric</b> condition
R	<b>Rare</b> disease
S	<b>Serious</b> , life-threatening condition

**Note:** a combination of codes may be applied to fully reflect points of consideration [eg, therapy may represent an advance in the treatment of a life-threatening condition with limited treatment alternatives (ASL)]

### EVIDENCE CONSIDERED:

\*to meet requirements 2 and 4

CITATION	LITERATURE CODE
----------	-----------------

Suddle A, Reeves H, Hubner R, Marshall A, Rowe I, Tiniakos D, Hubscher S, Callaway M, Sharma D, See TC, Hawkins M, Ford-Dunn S, Selemani S, Meyer T. British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults. Gut. 2024 Jul 11;73(8):1235-1268. doi: 10.1136/gutjnl-2023-331695. PMID: 38627031; PMCID: PMC11287576	S
Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, Satoh T, Marino D, Assenat E, Li S, Chen Y, Boisserie F, Abdrashitov R, Finn RS, Vogel A, Zhu AX. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003. PMID: 37796513; PMCID: PMC10557031.	S

Literature evaluation codes: S = Literature selected; 1 = Literature rejected = Topic not suitable for scope of content; 2 = Literature rejected = Does not add clinically significant new information; 3 = Literature rejected = Methodology flawed/Methodology limited and unacceptable; 4 = Other (review article, letter, commentary, or editorial)

#### CONTRIBUTORS:

\*to meet requirement 3

PACKET PREPARATION	DISCLOSURES
Stacy LaClaire, PharmD	None
Deanna Rossi, Pharm D	None

#### ASSIGNMENT OF RATINGS:

\*to meet requirement 4

	EFFICACY	STRENGTH OF RECOMMENDATION	STRENGTH OF EVIDENCE
MERATIVE MICROMEDEX	Evidence Favors Efficacy	Class IIB	B